Literature DB >> 10755520

Blocking the CD28-B7 T-cell costimulatory pathway abrogates the development of obliterative bronchiolitis in a murine heterotopic airway model.

A Yamada1, K Konishi, G L Cruz, M Takehara, M Morikawa, I Nakagawa, M Murakami, T Abe, S Todo, T Uede.   

Abstract

BACKGROUND: CTLA4IgG that binds to B7 effectively inhibits the signaling of CD28/B7 pathway and induces antigen-specific T-cell unresponsiveness in vitro and in vivo. We examined whether the development of obliterative bronchiolitis in a murine heterotopic airway transplantation model is T cell dependent and whether CTLA4IgG abrogates the development of obliterative bronchiolitis.
METHODS: Tracheae with main bronchi from C3H/He (H2k), BALB/C (H2d), or C57BL/6 (H2b) mice were transplanted heterotopically into subcutaneous pockets on the backs of BALB/C or BALB/C nu/nu mice on day 0. Recipient mice were untreated or intraperitoneally treated with either CTLA4IgG or human IgG with different time and dose schedules.
RESULTS: The development of obliterative bronchiolitis, which leads to luminal obliteration by fibrous tissue in a murine heterotopic airway transplantation model, was T cell dependent and the development of obliterative bronchiolitis was significantly abrogated by the CTLA4IgG treatment. However, the normal ciliated columnar respiratory epithelial cells in allografts were lost and replaced by flattened attenuated epithelial cells even after the CTLA4IgG treatment. We further demonstrated that CTLA4IgG treatment did not result in the induction of donor-specific unresponsiveness.
CONCLUSIONS: We demonstrated that the development of obliterative bronchiolitis in a murine heterotopic airway model involves both CD28/B7-dependent and -independent processes. The luminal obliteration by fibrous tissue is clearly CD28/B7 dependent and can be inhibited by CTLA4IgG. The luminal obliteration of allografted trachea by fibrous tissues and the loss of ciliated columnar respiratory epithelial cells represent distinct disease processes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755520     DOI: 10.1097/00007890-200003150-00012

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

Review 1.  Human and murine obliterative bronchiolitis in transplant.

Authors:  John F McDyer
Journal:  Proc Am Thorac Soc       Date:  2007-01

2.  Combined donor specific transfusion and anti-CD154 therapy achieves airway allograft tolerance.

Authors:  W Chalermskulrat; K P McKinnon; W J Brickey; I P Neuringer; R C Park; D G Sterka; B R Long; P McNeillie; R J Noelle; J P Ting; R M Aris
Journal:  Thorax       Date:  2005-10-27       Impact factor: 9.139

3.  Blockade of both B7-H4 and CTLA-4 co-signaling pathways enhances mouse islet allograft survival.

Authors:  Xiaojie Wang; Jianqiang Hao; Daniel L Metzger; Alice Mui; I-Fang Lee; Noushin Akhoundsadegh; C Lieping Chen; Dawei Ou; Ziliang Ao; C Bruce Verchere; Garth L Warnock
Journal:  Islets       Date:  2012-07-01       Impact factor: 2.694

Review 4.  Animal models for bronchiolitis obliterans syndrome following human lung transplantation.

Authors:  Elbert Kuo; Ankit Bharat; Sekhar Dharmarajan; Felix Fernandez; G Alec Patterson; T Mohanakumar
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 5.  Science of composite tissue allotransplantation.

Authors:  Bruce Swearingen; Kadiyala Ravindra; Hong Xu; Shengli Wu; Warren C Breidenbach; Suzanne T Ildstad
Journal:  Transplantation       Date:  2008-09-15       Impact factor: 4.939

Review 6.  The heterotopic tracheal allograft as an animal model of obliterative bronchiolitis.

Authors:  D J Hele; M H Yacoub; M G Belvisi
Journal:  Respir Res       Date:  2001-04-05

7.  Effect of CTLA4-Ig on Obliterative Bronchiolitis in a Mouse Intrapulmonary Tracheal Transplantation Model.

Authors:  Yamato Suzuki; Hisashi Oishi; Masahiko Kanehira; Yasushi Matsuda; Takashi Hirama; Masafumi Noda; Yoshinori Okada
Journal:  Ann Thorac Cardiovasc Surg       Date:  2021-05-12       Impact factor: 1.520

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.